Online citations, reference lists, and bibliographies.
← Back to Search

Multiplexed Immunofluorescence Reveals Potential PD-1/PD-L1 Pathway Vulnerabilities In Craniopharyngioma

S. Coy, Rumana Rashid, Jia-Ren Lin, Z. Du, A. Donson, T. Hankinson, N. Foreman, P. Manley, M. Kieran, D. Reardon, P. Sorger, S. Santagata
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background Craniopharyngiomas are neoplasms of the sellar/parasellar region that are classified into adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP) subtypes. Surgical resection of craniopharyngiomas is challenging, and recurrence is common, frequently leading to profound morbidity. BRAF V600E mutations render PCP susceptible to BRAF/MEK inhibitors, but effective targeted therapies are needed for ACP. We explored the feasibility of targeting the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint pathway in ACP and PCP. Methods We mapped and quantified PD-L1 and PD-1 expression in ACP and PCP resections using immunohistochemistry, immunofluorescence, and RNA in situ hybridization. We used tissue-based cyclic immunofluorescence to map the spatial distribution of immune cells and characterize cell cycle and signaling pathways in ACP tumor cells which intrinsically express PD-1. Results All ACP (15 ± 14% of cells, n = 23, average ± SD) and PCP (35 ± 22% of cells, n = 18) resections expressed PD-L1. In ACP, PD-L1 was predominantly expressed by tumor cells comprising the cyst lining. In PCP, PD-L1 was highly expressed by tumor cells surrounding the stromal fibrovascular cores. ACP also exhibited tumor cell-intrinsic PD-1 expression in whorled epithelial cells with nuclear-localized beta-catenin. These cells exhibited evidence of elevated mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) signaling. Profiling of immune populations in ACP and PCP showed a modest density of CD8+ T cells. Conclusions ACP exhibit PD-L1 expression in the tumor cyst lining and intrinsic PD-1 expression in cells proposed to comprise an oncogenic stem-like population. In PCP, proliferative tumor cells express PD-L1 in a continuous band at the stromal-epithelial interface. Targeting PD-L1 and/or PD-1 in both subtypes of craniopharyngioma might therefore be an effective therapeutic strategy.
This paper references
10.18632/ONCOTARGET.3082
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
Z. Du (2015)
Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations.
S. Sekine (2002)
10.1038/ng.2868
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
P. Brastianos (2014)
10.4049/jimmunol.1001323
CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes
B. Nelson (2010)
10.3171/JNS.1990.73.1.0012
Correlation of clinical and pathological features in surgically treated craniopharyngiomas.
T. E. Adamson (1990)
10.1111/bpa.12148
Insights into the Infiltrative Behavior of Adamantinomatous Craniopharyngioma in a New Xenotransplant Mouse Model
C. Stache (2015)
10.1093/jnci/djv310
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
P. Brastianos (2016)
10.3171/FOC.1997.3.6.4
The descriptive epidemiology of craniopharyngioma.
G. Bunin (1998)
10.1101/151738
A simple open-source method for highly multiplexed imaging of single cells in tissues and tumours
Jia-Ren Lin (2017)
10.1007/s11102-013-0543-8
Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche?
A. Hoelsken (2013)
10.1093/jnen/nlx061
Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma
A. Donson (2017)
10.3171/2016.9.FOCUS16308
Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Leslie C. Robinson (2016)
10.3171/2016.8.FOCUS16307
Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
J. Apps (2016)
10.1126/science.aaa1348
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)
10.1007/s11523-017-0510-9
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
O. Bylicki (2017)
10.1007/s00401-013-1212-8
Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma
Lindsey M. Hoffman (2013)
10.3171/2016.9.FOCUS16298
A quantitative analysis of craniopharyngioma cyst expansion during and after radiation therapy and surgical implications.
Kelly Lamiman (2016)
10.1158/2159-8290.CD-13-0310
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
E. Akbay (2013)
10.3171/2012.7.PEDS11436
Treatment-related morbidity and the management of pediatric craniopharyngioma: a systematic review.
A. Clark (2012)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
10.1016/S0002-9440(10)64477-X
Short Communication Craniopharyngiomas of Adamantinomatous Type Harbor -Catenin Gene Mutations
S. Sekine (2002)
10.1038/ncomms9390
Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method
Jia-Ren Lin (2015)
Adamantinomatous crani - opharyngiomas express tumor stem cell markers in cells with activated Wnt signaling : further evidence for the existence of a tumor stem cell niche ?
A Hölsken (2014)
10.1016/j.cell.2015.08.052
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
S. Kleffel (2015)
10.1038/nature13954
PD-1 blockade induces responses by inhibiting adaptive immune resistance
P. Tumeh (2014)
10.1093/neuonc/not026
Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011.
M. Cohen (2013)
10.1186/s40478-016-0287-6
Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles
A. Hoelsken (2016)
10.1007/s00401-005-1004-x
Common mutations of β-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region
R. Buslei (2005)
10.1038/ncomms13354
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee (2016)
10.1038/modpathol.2017.89
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
10.1002/cpch.14
Cyclic Immunofluorescence (CycIF), A Highly Multiplexed Method for Single‐cell Imaging
Jia-Ren Lin (2016)
10.1007/s00381-005-1190-9
The pathogenesis of craniopharyngiomas
V. Prabhu (2005)
WHO classification of tumours of the central nervous system
D. N. Louis (2007)
10.1016/j.wneu.2015.08.059
Quality of Life and Clinical Features of Long-Term Survivors Surgically Treated for Pediatric Craniopharyngioma.
S. Yano (2016)
10.1158/1078-0432.CCR-10-2811
EGFR Signaling Regulates Tumor Cell Migration in Craniopharyngiomas
A. Hoelsken (2011)
10.1007/s00401-007-0243-4
The 2007 WHO Classification of Tumours of the Central Nervous System
D. N. Louis (2007)
10.1038/modpathol.2016.153
Distinct patterns of primary and motile cilia in Rathke’s cleft cysts and craniopharyngioma subtypes
S. Coy (2016)
10.1530/EJE-15-0957
ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
P. Brastianos (2016)
10.1055/s-0034-1368785
Childhood craniopharyngioma - changes of treatment strategies in the trials KRANIOPHARYNGEOM 2000/2007.
A. Hoffmann (2014)



This paper is referenced by
10.1038/s41597-019-0332-y
Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer
Rumana Rashid (2019)
10.1007/978-3-030-04152-6_30
Craniopharyngioma: Current Classification, Management, and Future Directions
Z. Habibi (2019)
10.3171/2019.10.FOCUS19705
Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Astrid C Hengartner (2020)
10.1080/14737175.2018.1528874
Childhood-onset craniopharyngioma: latest insights into pathology, diagnostics, treatment, and follow-up
A. Bogusz (2018)
10.1200/PO.18.00190
Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade.
I. Dunn (2018)
10.7150/thno.45219
Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration
J. Jin (2020)
10.1007/s00381-020-04677-5
Adamantinomatous craniopharyngioma in the molecular age and the potential of targeted therapies: a review
Ros Whelan (2020)
10.1016/j.wneu.2020.05.173
Creative and Innovative Methods and Techniques for the Challenges in the Management of Adult Craniopharyngioma.
Hirokazu Takami (2020)
10.1038/s41596-019-0206-y
Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging
Z. Du (2019)
10.1101/2020.03.27.001834
Interpretative guides for interacting with tissue atlas and digital pathology data using the Minerva browser
Rumana Rashid (2020)
10.1159/000507084
Histopathology of Parasellar Neoplasms
E. Manojlović-Gačić (2020)
10.1016/j.bbrc.2019.04.142
Frequent B7-H3 overexpression in craniopharyngioma.
C. Chen (2019)
10.3390/jcm9020519
The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
Ros Whelan (2020)
10.1016/j.wneu.2019.02.212
Immune Microenvironment of Primary and Recurrent Craniopharyngiomas: A Study of the Differences and Clinical Significance.
D. Lin (2019)
10.1101/2020.03.27.001834
Online narrative guides for illuminating tissue atlas data and digital pathology images
Rumana Rashid (2020)
10.1038/s41390-020-1013-4
Clinical features and prognosis of pediatric infradiaphragmatic craniopharyngioma relative to the tumor inflammatory response
Jun-xiang Peng (2020)
10.1101/704114
Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer
Rumana Rashid (2019)
10.31487/J.COR.2019.03.05
Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma
Cynthia Kassab (2019)
10.1007/978-3-030-41176-3
Adult Craniopharyngiomas: Differences and Lessons from Paediatrics
Emmanuel Jouanneau (2020)
10.1007/978-3-030-41176-3_12
Molecular Targets in Craniopharyngioma
Elham Rostami (2020)
Semantic Scholar Logo Some data provided by SemanticScholar